Is ghrelin a biomarker in psoriatic arthritis?

SAVIO V; DEMARCHI M; CANTARELLI V; PONZIO MF; YORIO M; CASTRILLÓN ME; ALBA PB; MARTINI AC

Córdoba

Jornada; XXIV Jornada de Investigación de la Facultad de Ciencias Médicas.; 2023

Secretaría de Ciencias y Tecnología - Facultad de Ciencias Médicas - UNC

Psoriatic disease (PDs), which includes psoriasis (PsO) and psoriatic arthritis (PsA), is usually associated with cardiometabolic comorbidities. Ghrelin (Ghrl) is a polypeptide with cardioprotective, immunomodulatory and anti-inflammatory effects. Few studies have explored the relationship with PsO and none with PsA.Our objective was to evaluate ghrelinemia in patients with PsA, its relationship with disease activity, metabolic and cardiovascular status.A prospective case-control cross-sectional study was performed (between 7/2019 and 3/2022). Sixty-nine PsA patients matched by sex and age with PsO (n=43) and controls (CT; n=51) were included. Patients with another inflammatory joint disease were excluded. Activity was evaluated by PASI (psoriasis area severity index), DAPSA (disease activity for psoriatic arthritis) and MDA (minimal disease activity). Subclinical atherosclerosis (SCate) was defined according to myointimal thickening ≥0.9mm and/or presence of carotid plaque by ultrasound (excluding those with a previous cardiovascular event), and metabolic syndrome (MetS) by ATPIII. ANOVA or Kruskall-Wallis tests were applied and p0.05) and no differences were found between groups according to PASI or DAPSA. Patients with PsA and PsO showed a higher frequency of ATEsc than CT (57% and 68% vs 36%, respectively; p